Sign in
Taking peoplePhase 1

NG004 antibody for adults with recent incomplete spinal cord injury in the neck

Tests the antibody NG004 against placebo in adults with recent incomplete neck spinal cord injury.

Key facts

Who runs it
NovaGo Therapeutics AG
Where
Germany8 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
A randomized, double-blind, placebo-controlled clinical trial to investigate the human monoclonal antibody NG004 in acute, incomplete cervical spinal cord injury (SCI) patients
Status
Recruiting
Phase
Phase 1
People taking part
84 people, planned
Started
21 Sept 2026
Expected to end
30 Jun 2029
Type of study
Interventional
Record updated
14 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a recent (acute), incomplete injury of the spinal cord in the neck. It tests the antibody NG004 against a placebo (dummy treatment).

Age
18 years and older
Sex
All sexes
Disease stage
Acute, incomplete cervical (neck) spinal cord injury

Main reasons for not taking part

  • Healthy volunteers cannot join

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
NG004 antibody for adults with recent incomplete spinal cord injury in the neckGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
14 October 2026